Nasdaq · CIK 0001528287
NPCE NeuroPace Inc
Insider trading from SEC Form 4. Last filing 18 d ago. Close $13.00 on Oct 12, 2026, +38% from the 52-week low and -33% from the high.
In brief
NeuroPace Inc (NPCE) has 86 SEC Form 4 filings on file from 12 insiders, the latest filed on Sep 25, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
12 open-market trades have been scored at NPCE. The newest: Martha Morrell (CHIEF MEDICAL OFFICER) sold $399k of stock on Dec 15, 2025, filed Mar 4, 2026, scored 21 (weak), under a 10b5-1 plan. The largest of the 12 shown: Kck Ltd. (10% owner) sold $50M on Feb 20, 2025, scored 57 (moderate). 2 insiders sold within 14 days of each other around Dec 6, 2023.
9 Form 144 notices of planned sales are on file, the latest filed Dec 15, 2025.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at NeuroPace Inc, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 21Weak | Martha Morrell CHIEF MEDICAL OFFICER sell | $399k 25,000 shares | -33% | +93% from low-12% from high | |
| 37Weak | Orbimed Advisors LLC owner sell | $2.7M 168,136 shares | -5% | +164% from low0% from high | |
| 57Moderate | Kck Ltd. owner sell | $50M 5,270,845 shares | -100% | - | |
| 37Weak | Kck Ltd. owner sell | $1.2M 224,138 shares | -4% | - | |
| 12Weak | Kck Ltd. owner sell | $25k 4,082 shares | -0% | - | |
| 19Weak | Kck Ltd. owner sell | $53k 8,598 shares | -0% | - | |
| 26Weak | Kck Ltd. owner sell | $303k 46,426 shares | -1% | - | |
| 11Weak | Martha Morrell Chief Medical Officer sell | $136k 13,402 shares | -11% | +667% from low0% from high | |
| 0Weak | Martha Morrell Chief Medical Officer sell | $28k 2,730 shares | -2% | +619% from low-6% from high | |
| 12Weak | Martha Morrell Chief Medical Officer sell | $90k 11,005 shares | -8% | +537% from low-16% from high | |
| 31Weak | Kck Ltd. owner sell | $142k 16,167 shares | -0% | +578% from low-10% from high | |
| 30Weak | Kck Ltd. owner sell | $99k 11,171 shares | -0% | +587% from low-9% from high |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Dec 15, 2025 | MARTHA J MORRELL Officer | 25,000 0.08% of outstanding | $405k | Dec 15, 2025 | none |
| Jan 30, 2025 | MARTHA J MORRELL Officer | 78,534 0.26% of outstanding | $1.2M | Jan 30, 2025 | $50k |
| Jan 29, 2025 | MARTHA J MORRELL Officer | 100 0.00% of outstanding | $1,413 | Jan 29, 2025 | $48k |
| Jan 24, 2025 | MARTHA J MORRELL Officer | 3,200 0.01% of outstanding | $45k | Jan 24, 2025 | none |
| Oct 28, 2024 | KCK LTD. 10% Stockholder | 223,991 0.77% of outstanding | $1.2M | Oct 25, 2024 | $657k |
| Mar 15, 2024 | Irina Ridley Chief Legal Officer | 3,936 0.01% of outstanding | $54k | Mar 15, 2024 | none |
| Dec 20, 2023 | Martha Morrell Chief Medical Officer | 48,397 0.18% of outstanding | $483k | Dec 20, 2023 | $90k |
| Dec 6, 2023 | Martha Morrell Affiliate | 11,005 0.04% of outstanding | $90k | Dec 6, 2023 | none |
| Nov 29, 2023 | KCK Ltd. Shareholder | 262,836 1.00% of outstanding | $2.3M | Nov 27, 2023 | none |
Transactions
The newest 50 of 174 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 24, 2026 | Martha Morrell CHIEF MEDICAL OFFICER | FTax withholding Common Stock | -335 | $13.97 | $4,680 | 51,357 | 18 d ago |
| Sep 20, 2026 | Patrick F. Williams Chief Financial Officer | FTax withholding Common Stock | -1,162 | $14.28 | $17k | 67,508 | 22 d ago |
| Sep 3, 2026 | Joel Becker CHIEF EXECUTIVE OFFICER | FTax withholding Common Stock | -1,310 | $14.75 | $19k | 138,000 | 39 d ago |
| Aug 27, 2026 | Martha Morrell CHIEF MEDICAL OFFICER | FTax withholding Common Stock | -358 | $14.13 | $5,059 | 51,692 | Aug 28, 2026 |
| Aug 27, 2026 | Joel Becker CHIEF EXECUTIVE OFFICER | FTax withholding Common Stock | -1,126 | $14.13 | $16k | 139,310 | Aug 28, 2026 |
| Jun 24, 2026 | Martha Morrell CHIEF MEDICAL OFFICER | FTax withholding Common Stock | -335 | $16.22 | $5,434 | 52,050 | Jun 25, 2026 |
| Jun 19, 2026 | Uri Geiger director | AGrant or award Common Stock | +789 | $15.63 | $12k | 18,537 | Jun 22, 2026 |
| Jun 19, 2026 | Rakhi Kumar director | AGrant or award Common Stock | +989 | $15.63 | $15k | 23,039 | Jun 22, 2026 |
| Jun 19, 2026 | Frank M Fischer director | AGrant or award Common Stock | +1,467 | $15.63 | $23k | 599,534 | Jun 22, 2026 |
| Jun 5, 2026 | Renee Ryan director | AGrant or award Common Stock | +2,890 | $0.00 | $0 | 2,890 | Jun 5, 2026 |
| Jun 5, 2026 | Rakhi Kumar director | AGrant or award Common Stock | +2,890 | $0.00 | $0 | 22,050 | Jun 5, 2026 |
| Jun 5, 2026 | Lisa Andrade director | AGrant or award Common Stock | +2,890 | $0.00 | $0 | 2,890 | Jun 5, 2026 |
| Jun 5, 2026 | R Scott Huennekens director | AGrant or award Common Stock | +2,890 | $0.00 | $0 | 2,890 | Jun 5, 2026 |
| Jun 5, 2026 | Frank M Fischer director | AGrant or award Common Stock | +2,890 | $0.00 | $0 | 598,067 | Jun 5, 2026 |
| Jun 5, 2026 | Uri Geiger director | AGrant or award Common Stock | +2,890 | $0.00 | $0 | 17,748 | Jun 5, 2026 |
| Jun 5, 2026 | R Scott Huennekens director | AGrant or award Stock Option (Right to Buy)derivative | +5,368 | $0.00 | $0 | 5,368 | Jun 5, 2026 |
| Jun 5, 2026 | Rakhi Kumar director | AGrant or award Stock Option (Right to Buy)derivative | +5,368 | $0.00 | $0 | 5,368 | Jun 5, 2026 |
| Jun 5, 2026 | Lisa Andrade director | AGrant or award Stock Option (Right to Buy)derivative | +5,368 | $0.00 | $0 | 5,368 | Jun 5, 2026 |
| Jun 5, 2026 | Renee Ryan director | AGrant or award Stock Option (Right to Buy)derivative | +5,368 | $0.00 | $0 | 5,368 | Jun 5, 2026 |
| Jun 5, 2026 | Frank M Fischer director | AGrant or award Stock Option (Right to Buy)derivative | +5,368 | $0.00 | $0 | 5,368 | Jun 5, 2026 |
| Jun 5, 2026 | Uri Geiger director | AGrant or award Stock Option (Right to Buy)derivative | +5,368 | $0.00 | $0 | 5,368 | Jun 5, 2026 |
| Jun 3, 2026 | Joel Becker CHIEF EXECUTIVE OFFICER | FTax withholding Common Stock | -1,255 | $15.88 | $20k | 140,436 | Jun 4, 2026 |
| May 27, 2026 | Joel Becker CHIEF EXECUTIVE OFFICER | FTax withholding Common Stock | -1,126 | $17.06 | $19k | 141,691 | May 28, 2026 |
| May 27, 2026 | Martha Morrell CHIEF MEDICAL OFFICER | FTax withholding Common Stock | -358 | $17.06 | $6,107 | 52,385 | May 28, 2026 |
| May 15, 2026 | Joel Becker CHIEF EXECUTIVE OFFICER | AGrant or award Common Stock | +45,880 | $0.00 | $0 | 142,817 | May 19, 2026 |
| May 15, 2026 | Martha Morrell CHIEF MEDICAL OFFICER | AGrant or award Common Stock | +5,460 | $0.00 | $0 | 52,743 | May 19, 2026 |
| May 15, 2026 | Patrick F. Williams Chief Financial Officer | AGrant or award Common Stock | +16,820 | $0.00 | $0 | 68,670 | May 19, 2026 |
| May 15, 2026 | Joel Becker CHIEF EXECUTIVE OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +122,190 | $0.00 | $0 | 122,190 | May 19, 2026 |
| May 15, 2026 | Martha Morrell CHIEF MEDICAL OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +14,550 | $0.00 | $0 | 14,550 | May 19, 2026 |
| May 15, 2026 | Patrick F. Williams Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +44,800 | $0.00 | $0 | 44,800 | May 19, 2026 |
| Mar 24, 2026 | Martha Morrell CHIEF MEDICAL OFFICER | FTax withholding Common Stock | -1,341 | $13.27 | $18k | 47,283 | Mar 25, 2026 |
| Mar 20, 2026 | Uri Geiger director | AGrant or award Common Stock | +913 | $13.00 | $12k | 14,858 | Mar 24, 2026 |
| Mar 20, 2026 | Joseph Lacob director | AGrant or award Common Stock | +865 | $13.00 | $11k | 14,754 | Mar 24, 2026 |
| Mar 20, 2026 | Frank M Fischer director | AGrant or award Common Stock | +1,826 | $13.00 | $24k | 595,177 | Mar 23, 2026 |
| Mar 20, 2026 | Rakhi Kumar director | AGrant or award Common Stock | +1,153 | $13.00 | $15k | 19,160 | Mar 23, 2026 |
| Mar 3, 2026 | Joel Becker CHIEF EXECUTIVE OFFICER | FTax withholding Common Stock | -5,023 | $13.83 | $69k | 96,937 | Mar 4, 2026 |
| Dec 15, 2025 | Martha Morrell CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock10b5-1 | -25,000 | $15.97 | $399k | 49,964 | Mar 4, 2026 |
| Mar 3, 2026 | Martha Morrell CHIEF MEDICAL OFFICER | FTax withholding Common Stock | -1,340 | $13.83 | $19k | 48,624 | Mar 4, 2026 |
| Feb 27, 2026 | Joel Becker CHIEF EXECUTIVE OFFICER | FTax withholding Common Stock | -1,126 | $14.58 | $16k | 101,960 | Mar 2, 2026 |
| Feb 27, 2026 | Martha Morrell CHIEF MEDICAL OFFICER | FTax withholding Common Stock | -358 | $14.58 | $5,220 | 74,964 | Mar 2, 2026 |
| Feb 20, 2026 | Martha Morrell CHIEF MEDICAL OFFICER | FTax withholding Common Stock | -3,412 | $14.34 | $49k | 75,322 | Feb 23, 2026 |
| Dec 19, 2025 | Frank M Fischer director | AGrant or award Common Stock | +1,431 | $16.59 | $24k | 593,351 | Dec 23, 2025 |
| Dec 19, 2025 | Uri Geiger director | AGrant or award Common Stock | +715 | $16.59 | $12k | 13,945 | Dec 23, 2025 |
| Dec 19, 2025 | Rakhi Kumar director | AGrant or award Common Stock | +904 | $16.59 | $15k | 18,007 | Dec 23, 2025 |
| Dec 19, 2025 | Joseph Lacob director | AGrant or award Common Stock | +678 | $16.59 | $11k | 13,889 | Dec 23, 2025 |
| Dec 3, 2025 | Martha Morrell CHIEF MEDICAL OFFICER | FTax withholding Common Stock | -1,338 | $16.66 | $22k | 78,734 | Dec 4, 2025 |
| Nov 27, 2025 | Joel Becker CHIEF EXECUTIVE OFFICER | FTax withholding Common Stock | -1,126 | $16.50 | $19k | 103,086 | Dec 1, 2025 |
| Nov 27, 2025 | Martha Morrell CHIEF MEDICAL OFFICER | FTax withholding Common Stock | -357 | $16.50 | $5,891 | 80,072 | Dec 1, 2025 |
| Nov 20, 2025 | Martha Morrell CHIEF MEDICAL OFFICER | FTax withholding Common Stock | -3,051 | $13.50 | $41k | 80,429 | Nov 24, 2025 |
| Sep 19, 2025 | Frank M Fischer director | AGrant or award Common Stock | +2,389 | $9.94 | $24k | 591,920 | Sep 22, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Lisa Andradedirector
- Joel BeckerChief Executive Officer
- Frank M Fischerdirector
- Uri Geigerdirector
- R Scott Huennekensdirector
- Kck Ltd.owner
- Rakhi Kumarofficer, director
- Joseph Lacobdirector
- Martha MorrellChief Medical Officer
- Orbimed Advisors LLCdirector, owner
- Renee Ryandirector
- Patrick F. WilliamsChief Financial Officer
Questions about NPCE
Answered from the filings on this page, as of the latest one.
Are insiders buying NPCE?
No. In the last 90 days no insider at NeuroPace Inc bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade NPCE on the open market?
Martha Morrell (CHIEF MEDICAL OFFICER) sold $399k of NPCE on Dec 15, 2025 and filed the Form 4 on Mar 4, 2026. InsiderTell scored 21 (weak), under a 10b5-1 plan.
How many insiders file Form 4 at NeuroPace Inc?
12 people have filed a Form 4 at NeuroPace Inc, among them Lisa Andrade (director), Joel Becker (Chief Executive Officer), Frank M Fischer (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.